Skip to content
Preprint · CC-BY via OpenAlex

Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity

Brett Fulleylove-Krause, Samantha L. Sison, Allison D. Ebert

Research Square · 2020

Abstract

Abstract Objectives: Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. Although the underlying mechanisms of dopaminergic neuron loss is not fully understood, evidence suggests mitochondrial malfunction as a key contributor to disease pathogenesis. We previously found that human PD patient stem cell-derived dopaminergic neurons exhibit reduced nicotinamide adenine dinucleotide (NAD+) levels and reduce activity of sirtuins, a group of NAD+-dependent deacetylase enzymes that participate in the regulation of mitochondrial function, energy production, and cell survival. Thus, here we tested whether treatment of PD stem cell-derived dopaminergic neurons with nicotinamide mononucleotide (NMN), an NAD+ precursor, could increase NAD+ levels and improve sirtuin activity. Results: We treated PD iPSC-derived dopaminergic neurons with NMN and found that NAD+ levels did increase. The deacetylase activity of sirtuin (SIRT) 2 was improved with NMN treatment, but NMN had no impact on deacetylase activity of SIRT 1 or 3. These results suggest that NMN can restore NAD+ levels and SIRT 2 activity, but that additional mechanisms are involved SIRT 1 and 3 dysregulation in PD dopaminergic neurons.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.21203/rs.3.rs-43558/v1
Canonical
link ↗
Fetched
2026-10-09 MST

Cite this

APA
Fulleylove-Krause, B., Sison, S.L., &amp; Ebert, A.D. (2020). Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity. <em>Research Square</em>. https://doi.org/10.21203/rs.3.rs-43558/v1
Vancouver
Fulleylove-Krause B, Sison SL, Ebert AD. Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity. Research Square. 2020. doi:10.21203/rs.3.rs-43558/v1.
BibTeX
@unpublished{brett2020Nicoti, title = {Nicotinamide mononucleotide treatment increases NAD+ levels in an iPSC Model of Parkinson’s Disease but does not impact sirtuin activity}, author = {Brett Fulleylove-Krause and Samantha L. Sison and Allison D. Ebert}, journal = {Research Square}, year = {2020}, doi = {10.21203/rs.3.rs-43558/v1}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings